ERBB2 and breast cancer: Herein, we explore clinical, pathological, and molecular features associated with pCR, objective response (OR), BCS, and prognosis after NACT among patients with HR+/HER2- early BC included in the Sweden Cancerome Analysis Network-Breast (SCAN-B) cohort between 2010 and 2019.